[1] 周雪莲, 傅君芬. 儿童非酒精性脂肪肝病的诊断及治疗策略[J]. 中华儿科杂志, 2024, 62(6): 590-592. Zhou XL, Fu JF. Expert consensus on the diagnosis andtreatment of nonalcoholic fatty liver disease in children[J]. Chin J Pediatr, 2024, 62(6): 590-592. (in Chinese) [2] Nobili V, Alisi A, Valenti L, et al. NAFLD in children: New genes, new diagnostic modalities and new drugs[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(9): 517-530. [3] Guo X, Yin X, Liu Z, et al. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment[J]. Int J Mol Sci, 2022, 23(24): 15489. [4] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922. [5] Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: Biomarkers and non-invasive diagnostic tests[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(12): 835-856. [6] Brecelj J, Orel R. Non-alcoholic fatty liver disease in children[J]. Medicina, 2021, 57(7): 719. [7] 首都儿科研究所, 九市儿童体格发育调查协作组. 2016年中国九城市七岁以下儿童单纯性肥胖流行病学调查[J]. 中华儿科杂志, 2018, 56(10): 745-752. Capital Institute of Pediatrics,The Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children. A national epidemiological survey on obesity of children under seven years of age in nine cities of China in 2016[J]. Chin J Pediatr, 2018, 56(10): 745-752. [8] 周雪莲, 傅君芬. 儿童非酒精性脂肪肝病诊断与治疗专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 487-492. Zhou XL, Fu JF. Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children[J]. Chin J Pediatr, 2018, 33(7): 487-492.(in Chinese) [9] Pang Z, Lu Y, Zhou G, et al. MetaboAnalyst 6.0: Towards a unified platform for metabolomics data processing, analysis and interpretation[J]. Nucleic Acids Res, 2024, 52(W1): 398-406. [10] Mann JP, Jenkins B, Furse S, et al. Comparison of the lipidomic signature of fatty liver in children and adults[J]. J Pediatr Gastroenterol Nutr, 2022, 74(6): 734-741. [11] Hartley A, Santos Ferreira DL, Anderson EL, et al. Metabolic profiling of adolescent non-alcoholic fatty liver disease[J]. Wellcome Open Res, 2018, 3(19): 166. [12] Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis[J]. Prog Lipid Res, 2013, 52(1): 175-191. [13] Paradies G, Petrosillo G, Paradies V, et al. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease[J]. Cell Calcium, 2009, 45(6): 643-650. [14] Paradies G, Paradies V, Ruggiero FM, et al. Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(39): 14205-14218. [15] Mendham AE, Goedecke JH, Zeng Y, et al. Exercise training improves mitochondrial respiration and is associated with an altered intramuscular phospholipid signature in women with obesity[J]. Diabetologia, 2021, 64(7): 1642-1659. [16] Barr J, Caballería J, Martínez-Arranz I, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression[J]. J Proteome Res, 2012, 11(4): 2521-2532. [17] Gitto S, Schepis F, Andreone P, et al. Study of the serum metabolomic profile in nonalcoholic fatty liver disease: Research and clinical perspectives[J]. Metabolites, 2018, 8(1): 17. [18] Khusial RD, Cioffi CE, Caltharp SA, et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics[J]. Hepatol Commun, 2019, 3(10): 1311-1321. [19] Kordy K, Li F, Lee DJ, et al. Metabolomic predictors of non-alcoholic steatohepatitis and advanced fibrosis in children[J]. Front Microbiol, 2021, 12(12): 713234. [20] Chae W, Lee KJ, Huh KY, et al. Association of metabolic signatures with nonalcoholic fatty liver disease in pediatric population[J]. Metabolites, 2022, 12(9): 881. |